Sarcopenia Is Systemic Energy Failure, Not Just Muscle Loss

Sarcopenia — the progressive loss of muscle strength, mass, and physical performance that accompanies aging — affects hundreds of millions of older adults worldwide and is a leading driver of disability, falls, and premature death. Yet it remains chronically underdiagnosed and undertreated, partly because the medical community has long framed it as a problem intrinsic to skeletal muscle. A new Personal View published in Lancet Healthy Longevity by Luigi Ferrucci and colleagues at the National Institute on Aging challenges that narrow framing with a more integrated — and clinically consequential — hypothesis.

The authors propose that sarcopenia is best understood as a manifestation of systemic energetic failure. In their framework, muscle function is not a fixed tissue property but an emergent output of tightly coordinated physiological systems: neural activation sets the energy demand; cardiovascular and vascular networks deliver oxygen and metabolic substrates; mitochondria convert those inputs into ATP; and the musculoskeletal system translates that ATP into mechanical work. Aging progressively disrupts coordination across all these layers. When physiological demand chronically outstrips available energy supply, the result is reduced strength, increased fatigability, impaired recovery, and eventually mobility disability — the clinical picture of sarcopenia.

Three independent lines of evidence support this reframing. Epidemiologically, muscle strength is more tightly linked to disability and mortality than muscle mass, suggesting mass alone is a poor proxy for the underlying energetic capacity. Interventionally, strategies that successfully increase muscle mass often fail to improve physical function, indicating that tissue quantity is not the rate-limiting factor. Mechanistically, emerging research shows mitochondrial performance is constrained less by intrinsic mitochondrial defects and more by upstream failures in oxygen and substrate delivery.

The clinical implications are substantial. Fatigability and recovery time emerge as early, sensitive indicators of energetic failure — detectable before overt strength loss. Risk stratification should incorporate multisystem assessments rather than muscle mass measurements alone. And therapeutic strategies should aim to restore coordinated physiological function across neural, cardiovascular, and mitochondrial systems, not just stimulate muscle protein synthesis.

As a Personal View, this paper presents a conceptual hypothesis grounded in existing evidence rather than new primary data. The framework generates testable predictions that will need prospective validation. Nonetheless, it offers a compelling and actionable reorientation for clinicians managing older patients with declining physical function.